Inovio drops MERS and Lassa fever vaccines after early trials disappoint
Inovio will stop work on its vaccines for Lassa fever and for MERS after the shots didn’t produce results that were strong enough to take forward in future tests, the company said Thursday afternoon.
It’s disappointing news for a company that announced job cuts in July, a tactic meant to preserve resources for its lead DNA vaccine candidates for HPV and Covid-19. Earlier this month, the company reported that it had $282 million in cash, equivalents and short-term investments on the books, down from $401 million a year prior.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
